Opinion – Financial Times- Vaccine speed must not trump safety (Excerpts)
We all want a coronavirus vaccine. But no matter how urgently action is needed, it is imperative that the highest standards of quality, safety and efficacy are upheld. […] We must prioritise thorough validation of the results of pre-clinical and clinical trials by independent expert bodies. There is no place for political favour or national...
Read moreWhat worked well in the COVID-19 pandemic response and why we should make sure it is preserved for the next pandemic
The World Health Assembly Special Session on a Pandemic Treaty, which will convene health ministries from around the world in Geneva next week, offers a unique opportunity to take a look back and share some important lessons learnt from fighting the COVID-19 pandemic.
Read moreNew research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D
• Report produced by leading R&D based pharmaceutical companies calls for a coherent, comprehensive and integrated approach at global and national levels to minimize growth of resistance to antibiotics. Preventing resistance requires a joint approach from healthcare professionals, pharmaceutical industry, policy makers and individual citizens to work together to promote appropriate antibiotic use. • Report...
Read moreCOVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain collective stumbling blocks
To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live. Several...
Read more@WorldIPDay: Women working their magic on innovation in health
Every April 26, we celebrate World Intellectual Property Organization’s (WIPO) World Intellectual Property Day to recognize the role that intellectual property (IP) rights play in encouraging innovation and creativity. This year’s campaign celebrates the brilliance, ingenuity, curiosity and courage of the women who are driving change in our world and shaping our common future. I have dedicated my...
Read moreCOVID-19 Biopharmaceutical Industry – Regulatory Guiding Principles (May 2020)
During these unprecedented times, it is essential that we all come together to contribute to the development of medicines and vaccines for treatment and prevention of COVID-19. Many activities, undertaken by governments, national regulatory authorities (NRAs), academia, global health stakeholders and the biopharmaceutical industry, are helping to identify, research, develop and manufacture at scale these...
Read moreFrom resistance to resilience: what could the future antibiotic pipeline look like?
In a new report, IFPMA reviews the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest concern, and presents modelling data on the future of the pipeline.
Read more
Smart Testing in Personalised Healthcare – ctDNA is Set to Change the Companion Diagnostic Landscape
In the pursuit of truly personalised healthcare, AstraZeneca has entered into partnerships with Roche and QIAGEN for the clinical development of novel diagnostic tests based on circulating tumour DNA (ctDNA). These tests will move us to the next generation of companion diagnostics by allowing detection of recognised tumour mutations based on accurate analysis of minute quantities...
Read more4th global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D.
Read more